Xilio Therapeutics Announces Initiation of Enrollment for Ph

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1…

Updated Phase 1 monotherapy data for XTX101 at the recommended Phase 2 dose (RP2D) continues to demonstrate minimal treatment-related adverse events,…

Related Keywords

, Updated Phase , News , Ggregator , Reaking News , Uration , Media ,